Tax Inversions and Price Attacks: Will Wyden Make the Link?
This article was originally published in RPM Report
Finance Committee Chair Ron Wyden is promising immediate action to stop the trend of biopharma companies acquiring ex-US firms to reincorporate for tax reasons. The prospects for legislation are limited – but will the debate open up a new angle to attack biopharma pricing in the US?
You may also be interested in...
Sen. Warren’s “War on Pharma”: Rhetorical Blast, But Remarkably Limited Objectives
Despite her reputation as a populist, anti-corporate crusader, Elizabeth Warren did not focus on Big Pharma in her first years in the Senate. The headlines following a speech by Warren last week suggest that has changed – but the actual legislative proposal looks a lot different than the rhetoric makes it sound.
Pharma’s Adherence Allies: Part D Hearing Underscores Industry Progress in Reframing Rebate Debate
Sen. Bill Nelson is the primary sponsor of legislation to impose rebates on Medicare Part D. But when he held a hearing on the program in his Aging Committee, something surprising happened: everyone wanted to talk about adherence instead.
Pharma Blames EU IVD Regulation For Clinical Trial Delays
The challenges posed by the implementation of the EU IVD Regulation are having a negative impact on medicine trials using diagnostics. Many of such studies are currently stalled and research-based drug companies are calling on all partners to engage in dialog to find an urgent solution.